WilmerHale Successfully Represents Mayne in its Acquisition by Hospira

Download IconDownload Print IconPrint

WilmerHale Successfully Represents Mayne in its Acquisition by Hospira

Client News

Related Solutions

We offer clients exceptional insight in dealing with competition agencies in the United States, Europe and around the world.
Antitrust and Competition

WilmerHale successfully represented its client Mayne Pharma Ltd. before the US Federal Trade Commission to secure antitrust clearance of Mayne's acquisition by Hospira, Inc. The transaction will make Hospira one of the world's leading generic injectable drug manufacturers. The January 18, 2007 clearance decision required no divestitures material to the transaction and came only two and a half months after the Commission initiated a Second Request investigation.

The WilmerHale antitrust lawyers working on the transaction included William Kolasky, Jeff Ayer, Andrew Ewalt, Laura Hill, Alexander Krulic, Elizabeth de Luca, Jeffrey Schomig, Deirdre Waters, and Dan Matheson.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel